Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 551 - 575 of 11608 in total

Guanfacine

Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
Approved
Investigational
Matched Description: … Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially …

Sofosbuvir

Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the...
Approved
Matched Description: … Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy ... HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 ... As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent …

Fursultiamine

Compound used for therapy of thiamine deficiency. It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Approved
Matched Description: … Fursultiamine is a vitamin B1 derivative. …

Guanadrel

Guanadrel is an antihypertensive agent and postganglionic adrenergic blocking agent.
Approved

Desipramine

Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive...
Approved
Investigational
Matched Description: … See toxicity section below for a complete listing of side effects. ... In depressed individuals, desipramine exerts a positive effect on mood. ... Desipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). …
Matched Categories: … Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index …

Tirzepatide

Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials....
Approved
Investigational
Matched Description: … [A246260] Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty ... Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide ... [L41820] Later, it was approved under a different brand name ZEPBOUND on November 8, 2023, for the chronic …

Human interferon beta

Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis (MS), and was initially approved by the FDA in 1992. Multiple Sclerosis is a devastating neurodegenerative disease that is usually progressive and significantly debilitating with a profound impact on the quality of life. Interferon...
Approved
Investigational
Matched Description: … significantly debilitating with a profound impact on the quality of life. ... Human interferon beta is a polypeptide used in the management of relapsing forms of Multiple Sclerosis ... It is therefore a potential drug candidate for SARS-CoV-2 based on viral genetic similarity. …

Indacaterol

Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as...
Approved
Matched Description: … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed. ... Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis …

Buspirone

Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT1A receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does...
Approved
Investigational
Matched Description: … Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. ... Belonging to the azaspirodecanedione drug class,[A180991] buspirone is a serotonin 5-HT1A ... It has also been used as a second-line therapy for unipolar depression when the use of selective serotonin …

Methyldopa

Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading...
Approved
Matched Description: … Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. ... [A231784] It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug …

Satralizumab

Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to tocilizumab, which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune inflammatory disorder of the central...
Approved
Matched Description: … Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL- ... [L15536] Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare ... "recycling antibody technology" whereby the association of satralizumab to IL-6 receptors occurs in a …

Zopiclone

Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
Approved
Matched Description: … Zopiclone is a novel hypnotic agent used in the treatment of insomnia. …

Adalimumab

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor.[A39984,A39999] It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA. This drug is frequently known as Humira. It is produced...
Approved
Experimental
Matched Description: … [L49101] A biosimilar marketed as Hyrimoz, a high-concentration formulation of adalimumab, is also available ... It is produced by recombinant DNA technology using a mammalian cell expression system. ... Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid …

Alclofenac

Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Approved
Withdrawn
Matched Description: … Alclofenac is a non-steroidal anti-inflammatory drug. …

Apronalide

Apronalide is approved in Japan. Apronalide has been withdrawn from the market in many other countries due to patient development of thrombocytopenic purpura .
Approved

Atracurium

Approved
Experimental
Investigational

Fenofibric acid

Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia, and mixed dyslipidemia. It works to decrease elevated low-density lipoprotein cholesterol, total cholesterol, triglycerides, apolipoprotein B, while increasing high-density lipoprotein cholesterol.[A32038,L12855] Due to its high hydrophilicity and poor absorption profile, prodrug ,fenofibrate, and other conjugated compounds...
Approved
Matched Description: … Fenofibric acid is a lipid-lowering agent that is used in severe hypertriglyceridemia, primary hyperlipidemia …

Remestemcel-L

Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal stem cells intended for intravenous infusion. The mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells. It was...
Approved
Investigational
Matched Description: … risk for poor outcomes and creating a significant clinical challenge [A31818]. ... Remestemcel-L is a third-party, off-the-shelf suspension of ex-vivo cultured adult human mesenchymal ... aGvHD is a T-cell mediated disease that occurs after allogeneic hematopoietic stem cell transplant and …

Crotalus adamanteus antivenin

Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 . The eastern diamondback...
Approved
Experimental

Cholestyramine

Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water.
Approved
Investigational
Matched Description: … Cholestyramine or colestyramine is a bile acid sequestrant. …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Methoxy polyethylene glycol-epoetin beta

Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent (ESA) with a longer half-life than erythropoietin. ESA is used to increase synthesis of red blood cells to treat chronic kidney disease associated anemia.
Approved
Matched Description: … (ESA) with a longer half-life than erythropoietin. ... Methoxy polyethylene glycol-epoetin beta is a chemically synthesised Erythropoiesis Stimulating Agent …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Iothalamic acid

Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent.
Approved
Matched Description: … Iothalamic acid is an iodine containing organic anion used as a diagnostic contrast agent. …
Matched Categories: … Compounds used in a research, industrial, or household setting …

Efmoroctocog alfa

Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It is an antihemorrhagic agent used in replacement therapy for patients with haemophilia A (congenital factor VIII deficiency). It...
Approved
Investigational
Matched Description: … Haemophilia A is a rare bleeding disorder associated with a slow clotting process caused by the deficiency ... Factor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood ... Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life …

Fosdenopterin

Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a deficiency of three molybdenum-dependent enzymes: sulfite oxidase (SOX), xanthine dehydrogenase, and aldehyde oxidase. Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity.[A230088,L32163]...
Approved
Matched Description: … resulting from a lack of SOX activity. ... the first therapeutic option for patients with MoCD type A. ... Molybdenum cofactor deficiency (MoCD) is an exceptionally rare autosomal recessive disorder resulting in a …

Ivosidenib

Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivosidenib was granted accelerated approval by the FDA...
Approved
Investigational
Matched Description: … Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. ... The drug is only effective in patients with a susceptible IDH1 mutation. ... L48781] In February 2023, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a …
Matched Categories: … P-glycoprotein substrates with a Narrow Therapeutic Index ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Displaying drugs 551 - 575 of 11608 in total